Skip to main content

Advertisement

Table 1 Patient and treatment characteristics

From: Stereotactic radiation therapy for liver metastases: factors affecting local control and survival

  Patients
No. of patients evaluable/completing treatment 74/76
Gender Male 38
  Female 36
Age at treatment (years) Median 61 (range 40-80)
ECOG performance status Median 0 (range 0-2)
 0 50
 1 22
 2 2
Status of extrahepatic disease  
 NED (no evidence of disease) 39 (53%)
 SD/PD (stable/progressive) 35 (47%)
Previous treatment per irradiated lesion  
 No previous treatment 23 (25.3%)
 Chemotherapy 44 (48.4%)
 Endocrine therapy 3 (3.3%)
 Local therapy (surgery, radiofrequency ablation) 4 (4.4%)
 Combination of local and systemic treatment 17 (18.6%)
Follow up (months) Median 15 (range 3-103)
Primary tumor Colorectal 37
  Breast 12
  Esophageal 5
  Stomach/Pancreas/Bile duct 7
  Lung 2
  Other 11
  Lesions
Total No. of lesions evaluated/treated 91/95
Lesions per patient Mean 1.23 (range 1-4)
Total PTV dose at 60-95% IDL Median 35 (range 18-37.5)
(Gy)  
Single PTV dose at 60-95% IDL Median 7 (range 5-12.5)
(Gy)  
Fractions Median 5 (range 2-5)
Minimum BED to GTV Median 91.2 Gy (18.7-183.5Gy)
Gross tumor volume GTV (cc) Median 45 (range 1.3-699)
 <100 65
 100-200 12
 >200 12
Planning target volume PTV (cc) Median 123 (range 10.6-1074)